Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Neoplasma Vol.61, No.4, p.461-467, 2014 |
||
Title: PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer | ||
Author: Y. ZHANG, M. LIU, H. YANG, J. WANG, H. LIU, X. LI, J. LI, J. XU, X. LI | ||
Abstract: This study proposed to investigate the relationship of PIK3CA somatic mutations, the most common activating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy (NCT).Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN, EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93. |
||
Keywords: PIK3CA somatic mutation, NCT, breast cancer, epirubicin, docetaxel | ||
Published online: 25-Mar-2014 | ||
Year: 2014, Volume: 61, Issue: 4 | Page From: 461, Page To: 467 | |
doi:10.4149/neo_2014_057 |
||
|
download file |
|